Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Second Price Cut for PCSK9 Inhibitor Alirocumab (Praluent)The move brings the price down about 60% from the original cost of the cholesterol-lowering drug and brings alirocumab in line with the cost of its competitor PCSK9 inhibitor, evolocumab.
AlertAlirocumab (Praluent) to Get New Indication in EuropeThe European CHMP has also started a review of bleeding risks with the new oral anticoagulant agents and is reexamining its previous recommendation against use of omega 3 fatty acids after MI.
The Other Nutrition CrisisBy getting to the bottom of what is causing malnutrition in older adults, clinicians can help these patients live healthier, happier lives.
Medscape Family Medicine, February 13, 2019
Cardiology Topics to Watch for in 2019Wearables, aspirin for secondary prevention, AI and machine learning, and drug pricing are among the topics to keep an eye on in 2019, according to cardiologists Drs Harrington and Gibson.
theheart.org on Medscape, February 13, 2019
Supplements and CVD: Why Negative Data Don't Dampen SalesDietary supplements are a $133 billion industry globally, despite a lack of supportive data. Should healthcare providers do more to dissuade patients who persist in taking these pricey placebos?
